Plasma Chromogranin-A (CGA) - A potential marker for diagnosis, monitoring and management of prostate cancer patients

Harefuah

Volumn 145, Issue 1 SPEC. ISS., 2006, Pages 25-29

  Leibovitch, Ilan ^a   Pinthus, Yehonatan ^b   Sella, Ben Ami ^b,c   Ramon, Jacob ^b  

^a MEIR MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chromogranin A; Hormone refractory prostate cancer; Neuroendocrine; Prostate cancer; Prostatic specific antigen

Indexed keywords

CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN A, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REFERENCE VALUE;

CHROMOGRANIN A; CHROMOGRANINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 33644852498     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Nobles FR, Kwekkeboom DJ, Bouillon R & al, Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest, 1998; 28: 431-440.
2. Vashchenko N & Abrahamsson PA, Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol, 2005; 47: 147-155.
3. Nagakawa O, Fujiuchi Y, Fuse H & al, Differential effect of chromogranin A fragments on invasion and growth of prostate cancer cells in vitro. Urology, 2003; 62: 553-558.
4. Angelsen A, Syversen U, Stridsberg M & al, Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate, 1997; 31: 110-117.
5. Berruti A, Dogliotti L, Mosca A & al, Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer, 2000; 88: 2590-2597.
6. Berruti A, Mosca A, Tucci M & al, Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer, 2005; 12:109-117.
7. Deftos LJ, Nakada S, Burton DW & al, Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology, 1996; 48: 58-62.
8. Ferrero-Pous M, Hersant AM, Pecking A & al, Serum chromogranin-A in advanced prostate cancer. BJU Int, 2001; 88: 790-796.
9. Hvamstad T, Jordal A, Hekmat N & al, Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol, 2003; 44: 215-221.
10. Wu JT, Astill ME, Liu GH & al, Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal, 1998; 12: 20-25.
11. Wu JT, Wu TL, Chang CP & al, Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy. J Clin Lab Anal, 1999; 13: 308-311.
12. Sciarra A, Monti S, Gentile V & al, Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate, 2003; 55: 168-179.
13. Berruti A, Dogliotti L, Mosca A & al, Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol, 2001; 12: S153-157.
14. Sella A, Konichezky M, Flex D & al, Low PSA metastatic androgen-independent prostate cancer. Eur Urol, 2000; 38: 250-254.
15. Kamiya N, Akakura K, Suzuki H & al, Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol, 2003; 44: 309-314.
16. Nobels FR, Kwekkeboom DJ, Coopmans W & al, Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab, 1997; 82: 2622-2628.
17. Sciarra A, Voria G, Monti S & al, Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Prostate, 2004; 58: 421-428.
18. Sciarra A, Gentile V, Monti S & al, Variation of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma. Arch Androl, 2003; 49: 39-48.
19. Hirano D, Okada Y, Minei S & al, Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol, 2004; 45: 586-592.
20. Stridsberg M, Eriksson B, Oberg K & al, A comparison between three commercial kits for chromogranin A measurements. J Endocrinol, 2003; 177: 337-341.